Ductal Carcinoma In Situ: Risk Factors and Impact of Screening
Virnig BA, Wang SY, Shamilyan T, Kane RL, Tuttle TM. Ductal Carcinoma In Situ: Risk Factors and Impact of Screening. JNCI Monographs 2010, 2010: 113-116. PMID: 20956813, PMCID: PMC5161075, DOI: 10.1093/jncimonographs/lgq024.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingChemopreventionFemaleHormone Replacement TherapyHumansIncidenceMammographyMass ScreeningMiddle AgedMulticenter Studies as TopicRaloxifene HydrochlorideRandomized Controlled Trials as TopicRisk FactorsTamoxifenYoung AdultConceptsInvasive breast cancerBreast cancerDCIS incidenceDuctal carcinomaRisk factorsIncidence of DCISManagement of DCISRole of chemopreventionPositive family historyUse of mammographyImpact of screeningIncident DCISComedo necrosisMammography useFamily historyDCISHealth OfficeOlder ageIncidenceCancerNational InstituteCarcinomaFurther investigationAgeLiterature reviewAssociation Between Patient and Tumor Characteristics With Clinical Outcomes in Women With Ductal Carcinoma In Situ
Shamliyan T, Wang SY, Virnig BA, Tuttle TM, Kane RL. Association Between Patient and Tumor Characteristics With Clinical Outcomes in Women With Ductal Carcinoma In Situ. JNCI Monographs 2010, 2010: 121-129. PMID: 20956815, PMCID: PMC5161074, DOI: 10.1093/jncimonographs/lgq034.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedBody Mass IndexBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingFemaleGonadal Steroid HormonesHumansMammographyMenopauseNeoplasm Recurrence, LocalNeoplasms, Hormone-DependentPrognosisRacial GroupsRandomized Controlled Trials as TopicReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRiskSocioeconomic FactorsTreatment OutcomeTumor BurdenConceptsDuctal carcinomaClinical outcomesRecurrent cancerTumor characteristicsWorse outcomesNegative estrogen receptor statusAdvanced recurrent cancerPositive surgical marginsEstrogen receptor statusLarger tumor sizeHigh-risk categoryComposite prognostic indicesReceptor statusSurgical marginsPrognostic indexTumor sizeComedo necrosisPathological gradingClinical trialsObservational studyHigh riskHER2 receptorSynthesis of evidenceHigh mortalityYoung women